We can envision that DAXX can serve as a precise prognostic marker in PCa and that tissue-specific shRNA delivery targeted against DAXX can be employed in the treatment of metastatic prostate cancer in patients, in particular if we discover, through additional studies, that DAXX is a marker for lethal PCa in humans. Here, DAXX is linked to metastatic prostate carcinoma.